About 8,798 results

ALLMedicine™ Candidiasis Center

Research & Reviews  2,453 results

Pubertal development and hypogonadism in males with APECED - a retrospective study.
European Journal of Endocrinology; Träskilä E, Holopainen E et. al.

Mar 15th, 2023 - The aim of this study was to describe the course of puberty and hypogonadism in males with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in the Finnish APECED cohort followed 1970-2020. Anthropometry, testicular volumes, ...

Prevalence of and Prognostic Factors for Candida Superinfection in Oral Lichen Planus a...
Journal of Oral Pathology & Medicine : Official Publicati... Saepoo J, Kerdpon D et. al.

Mar 14th, 2023 - Oral candidiasis occasionally occurs in patients with oral lichen planus (OLP) or lichenoid reaction (OLR). However, not all patients undergoing corticosteroid therapy develop Candida superinfection. Thus, identification of prognostic risk factors...

Chemotherapy-Induced Oral Mucositis Treatment & Management

Mar 14th, 2023 - Approach Considerations Treatment of chemotherapy-induced oral mucositis begins with patient education and reinforcing the importance of good oral care throughout cancer treatment. Mucositis is self-limiting, and the goal of treatment is to make t...

Chemotherapy-Induced Oral Mucositis Treatment & Management

Mar 14th, 2023 - Approach Considerations Treatment of chemotherapy-induced oral mucositis begins with patient education and reinforcing the importance of good oral care throughout cancer treatment. Mucositis is self-limiting, and the goal of treatment is to make t...

Update on the treatment of chronic pulmonary aspergillosis.
Current Opinion in Infectious Diseases; Armstrong-James D, Kosmidis C et. al.

Mar 14th, 2023 - Chronic pulmonary aspergillosis is a major global infection in individuals with preexisting structural lung diseases and those with immunodeficiencies, in particular cytokine defects. Current treatment options are confined to just three drug class...

see more →

Guidelines  9 results

British HIV Association/British Infection Association guidelines on the management of o...
HIV Medicine 7 References; Dockrell DH, O’Shea D et. al.

Nov 2nd, 2019 - British HIV Association/British Infection Association guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019.|2019|Dockrell DH,O’Shea D,Cartledge JD,Freedman AR,|diagnosis,dru...

Microbiological Laboratory Testing in the Diagnosis of Fungal Infections in Pulmonary a...
American Journal of Respiratory and Critical Care Medicine; Hage CA, Carmona EM et. al.

Aug 31st, 2019 - Background: Fungal infections are of increasing incidence and importance in immunocompromised and immunocompetent patients. Timely diagnosis relies on appropriate use of laboratory testing in susceptible patients.Methods: The relevant literature r...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

Managing xerostomia and salivary gland hypofunction: executive summary of a report from...
Journal of the American Dental Association (1939); Plemons JM, Al-Hashimi I et. al.

Aug 2nd, 2014 - Xerostomia, also known as "dry mouth," is a common but frequently overlooked condition that is typically associated with salivary gland hypofunction, which is the objective measurement of reduced salivary flow. Patients with dry mouth exhibit symp...

Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.
Intensive Care Medicine; Montravers P, Dupont H et. al.

Oct 25th, 2013 - Intra-abdominal candidiasis: the guidelines-forgotten non-candidemic invasive candidiasis.|2013|Montravers P,Dupont H,Eggimann P,|therapeutic use,drug effects,drug therapy,microbiology,drug therapy,microbiology,

see more →

Drugs  506 results see all →

Clinicaltrials.gov  253 results

Oropharyngeal Candidiasis (OPC) and S-ECC

Mar 9th, 2023 - The overall goal of this study is to conduct a longitudinal observational study to investigate the association of early OPC with the onset and severity of S-ECC to better understand the role of Candida (particularly C. albicans) in severe childhoo...

Studies of Disorders With Increased Susceptibility to Fungal Infections

Mar 3rd, 2023 - This study is designed for the evaluation, diagnosis, and long-term follow up of selected patients with primary immune deficiencies and other conditions associated with fungal, and more specifically with Candida spp. infections. The primary immune...

A Study to Learn About the Study Medicine (Called Fosmanogepix/ PF-07842805) in People With Candidemia and/or Invasive Candidiasis.

Feb 27th, 2023 - The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Fosmanogepix) for the potential treatment of candidemia and/or invasive candidiasis, a life-threatening fungal infection caused by several sp...

Suppression Of Bacterial Vaginosis (BV) [SUBVert]

Feb 22nd, 2023 - This is a Phase II randomized, double-blind, placebo-controlled study screening approximately 600 adult females, aged 18-55, with a goal to enroll approximately 250 participants to achieve 200 evaluable participants at the test of cure (TOC) visit...

Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)

Feb 9th, 2023 - New rapid diagnostic strategies are warranted in intra-abdominal candidiasis (IAC). A previous retrospective study showed that one measure, the day of the surgery, of peritoneal 1.3-Beta-D-Glucan ≤ 310pg/ml could rule out an IAC. This strategy was...

see more →

News  282 results

Taltz Safety, Efficacy Stay Robust in Spondyloarthritis at 3 Years

Feb 21st, 2023 - Short-term improvements in axial spondyloarthritis (axSpA) symptoms seen with the interleukin-17A blocker ixekizumab (Taltz) persisted and even increased further among clinical trial participants who continued on the drug for 3 years, without any ...

FDA Panel Backs Weekly Rezafungin for Candidemia, Invasive Candidiasis

Jan 25th, 2023 - An FDA advisory committee on Tuesday overwhelmingly recommended approval, with a "limited use" indication, of long-acting rezafungin for the treatment of candidemia and invasive candidiasis (IC) in adults. By a vote of 14-1, the Antimicrobial Drug...

Will Rezafungin Data for Serious Candida Infections Sway FDA Panel?

Jan 23rd, 2023 - Ahead of an advisory committee meeting on Tuesday, FDA staff raised concerns over whether the potential benefits of weekly rezafungin injections for adults with candidemia and invasive candidiasis (IC) outweigh any potential risks, including neuro...

Phase III Trials Back Bimekizumab for Spondyloarthritis

Jan 17th, 2023 - Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said. With nearly 600 patients enrolled in two parallel phase III trials, 45% a...

FDA Approves Novel Dual Rescue Inhaler for Asthma in Adults

Jan 11th, 2023 - The FDA approved a pressured, metered-dose inhaler containing albuterol and budesonide (Airsupra) for treating adults with asthma, drugmaker AstraZeneca announced. The combination, formerly known as PT027, is specifically indicated for the as-need...

see more →

Patient Education  16 results see all →